Patents by Inventor Howard Jones
Howard Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11964393Abstract: A robot control system determines which of a number of discretizations to use to generate discretized representations of robot swept volumes and to generate discretized representations of the environment in which the robot will operate. Obstacle voxels (or boxes) representing the environment and obstacles therein are streamed into the processor and stored in on-chip environment memory. At runtime, the robot control system may dynamically switch between multiple motion planning graphs stored in off-chip or on-chip memory. The dynamically switching between multiple motion planning graphs at runtime enables the robot to perform motion planning at a relatively low cost as characteristics of the robot itself change. Various aspects of such robot motion planning are implemented in particular systems and methods that facilitate motion planning of the robot for various environments and tasks.Type: GrantFiled: July 12, 2023Date of Patent: April 23, 2024Assignee: REALTIME ROBOTICS, INC.Inventors: Daniel Sorin, George Konidaris, Sean Murray, William Floyd-Jones, Peter Howard, Xianchao Long
-
Patent number: 11959099Abstract: A method of altering cells comprising culturing them in a growth factor gradient, wherein said gradient is provided by a polyhedra delivery system (PODS) that releases the growth factor to set up the gradient.Type: GrantFiled: April 11, 2018Date of Patent: April 16, 2024Assignees: Cell Guidance Systems Limited, Yuka MatsuzaktInventors: Yuka Matsuzaki, Hajime Mori, Christian Pernstich, Michael Howard Jones
-
Publication number: 20240083900Abstract: Provided are compounds of Formula (I?): or pharmaceutically acceptable salts thereof, wherein the variables in the formula are as defined herein; and methods for their use and production.Type: ApplicationFiled: November 12, 2021Publication date: March 14, 2024Applicant: BIOGEN MA INC.Inventors: Brian T. Hopkins, Bin Ma, Isaac Marx, Jürgen Schulz, George Vandeveer, Robin Prince, Marta Nevalainen, TeYu Chen, Zain Yousaf, Martin Himmelbauer, Vatee Pattaropong, John Howard Jones, Edward Yin-Shiang Lin, Felix Gonzalez Lopez de Turiso, Thomas Purgett, Andrew George Capacci, Simone Sciabola
-
Patent number: 11873367Abstract: Novel polymers are depolymerizable by metathesis of a cleavable unit. As an example, a series of linear and crosslinked polyurethanes were prepared that can be selectively depolymerized under mild conditions. Two unique polyols were synthesized bearing unsaturated units in a configuration designed to favor ring-closing metathesis to five- and six-membered cycloalkenes. These polyols were co-polymerized with toluene diisocyanate to generate linear polyurethanes and trifunctional hexamethylene- and diphenylmethane-based isocyanates to generate crosslinked polyurethanes. The polyol design is such that the ring-closing metathesis reaction cleaves the backbone of the polymer chain. Upon exposure to dilute solutions of Grubbs' catalyst under ambient conditions, the polyurethanes were rapidly depolymerized to low molecular weight, soluble products bearing vinyl and cycloalkene functionalities. These functionalities enabled further re-polymerization by traditional strategies for polymerization of double bonds.Type: GrantFiled: April 29, 2021Date of Patent: January 16, 2024Assignee: National Technology & Engineering Solutions of Sandia, LLCInventors: Brad Howard Jones, Chad Lynn Staiger
-
Patent number: 11840586Abstract: The invention is directed to latent metathesis-active resin compositions and additive manufacturing approaches. The latent metathesis-active compositions comprise at least one latent metathesis catalyst, at least one curable metathesis-active monomer, and optional fillers, photosensitizers, and/or a secondary monomer resin system for dual-cure. A method comprises extruding a latent metathesis-active resin from a dispensing apparatus and spatially triggering a ring-opening metathesis polymerization by directed irradiation with light or directed application of a thermal stimuli for direct-ink write printing of objects. Another method uses a latent metathesis-active resin for vat photopolymerization and stereolithographic printing of objects.Type: GrantFiled: February 22, 2022Date of Patent: December 12, 2023Assignee: National Technology & Engineering Solutions of Sandia, LLCInventors: Leah Appelhans, Samuel Leguizamon, Brad Howard Jones, Adam Wade Cook
-
Publication number: 20230382892Abstract: The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula (I) or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, R2 and R3 are as defined in the description. HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).Type: ApplicationFiled: May 24, 2023Publication date: November 30, 2023Applicant: Pfizer Inc.Inventors: Ariamala Gopalsamy, Shawn Cabral, Agustin Casimiro Garcia, Ming Zhu Chen, Chulho Choi, Robert Lee Dow, Olugbeminiyi Omezia Fadeyi, David Hepworth, Jayasankar Jasti, Lyn Howard Jones, Arjun Venkat Narayanan, Mihir Dineshkumar Parikh, David Walter Piotrowski, Lee Richard Roberts, Ralph Pelton Robinson, Jr., Hatice Gizem Yayla
-
Publication number: 20230227646Abstract: Polymerization-induced phase separation enables fine control over thermoset network morphologies, yielding heterogeneous structures with domain sizes tunable over 1-100 nm. However, the controlled chain-growth polymerization techniques exclusively employed to regulate morphology at these length scales are unsuitable for most thermoset materials typically formed through step-growth mechanisms. By employing binary mixtures in place of the classic constituents of phase-separating thermosets—resin, curing agent, and secondary polymer—facile tunability over morphology can be achieved through a single compositional parameter. Indeed, this method yields morphologies spanning nano-scale to macro-scale, controlled by the relative reactivities and thermodynamic compatibility of the network components. Due to the connection between chain dynamics and microstructure in these materials, the tunable morphology enables exquisite control over glass transition and other physical and mechanical properties.Type: ApplicationFiled: January 17, 2022Publication date: July 20, 2023Inventors: Brad Howard Jones, Samuel Leguizamon
-
Patent number: 11702405Abstract: The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula (I) or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, R2 and R3 are as defined in the description. HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).Type: GrantFiled: April 12, 2021Date of Patent: July 18, 2023Assignee: Pfizer Inc.Inventors: Ariamala Gopalsamy, Shawn Cabral, Agustin Casimiro-Garcia, Ming Zhu Chen, Chulho Choi, Robert Lee Dow, Olugbeminiyi Omezia Fadeyi, David Hepworth, Jayasankar Jasti, Lyn Howard Jones, Arjun Venkat Narayanan, Mihir Dineshkumar Parikh, David Walter Piotrowski, Lee Richard Roberts, Ralph Pelton Robinson, Jr., Hatice Gizem Yayla
-
Publication number: 20230158157Abstract: Disclosed are bispecific compounds (degraders) that target ALK or ALK and FAK for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the bispecific compounds to treat diseases and disorders characterized or mediated by aberrant ALK or ALK and FAK activity.Type: ApplicationFiled: February 24, 2021Publication date: May 25, 2023Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: John M. Hatcher, Nathanael S. Gray, Baishan Jiang, Tinghu Zhang, Jianwei Che, Yang Gao, Lyn Howard Jones
-
Publication number: 20230098669Abstract: The invention is directed to the selective dual wavelength olefin metathesis polymerization for additive manufacturing. Dual-wavelength stereolithographic printing uses ring-opening metathesis polymerization of the metathesis-active polymers. As an example, a resin formulation based on dicyclopentadiene was produced using a photolatent olefin metathesis catalyst, various photosensitizers and photobase generators to achieve efficient initiation by light at one wavelength (e.g., blue) and fast catalyst decomposition and polymerization deactivation by light at a second wavelength (e.g., ultraviolet). This process enables 2-dimensional stereolithographic printing, either using photomasks or with patterned, collimated light. Importantly, the same process was readily adapted for 3-dimensional continuous additive manufacturing, with printing rates of up to 36 mm h?1 for patterned light and up to 180 mm h?1 using un-patterned, high intensity light.Type: ApplicationFiled: August 31, 2022Publication date: March 30, 2023Inventors: Samuel Carlos Leguizamon, Jeffrey Clayton Foster, Adam W. Cook, Leah Appelhans, Erica M. Redline, Brad Howard Jones
-
Publication number: 20230002397Abstract: Disclosed are compounds and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof that may cause degradation of various proteins e.g., IKZF2 (Helios). Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds to treat diseases and disorders associated with Helios and which may benefit from Helios degradation.Type: ApplicationFiled: October 29, 2020Publication date: January 5, 2023Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Nathanael S. Gray, Hu Liu, Tinghu Zhang, Lyn Howard Jones, Jianwei Che
-
Publication number: 20230000909Abstract: The invention relates to self-assembling proteins that are capable of being used to deliver cargo proteins to phagocytic cells, and the subsequent delivery and utility of these self-assembling proteins by the phagocytic cells at sites of disease. In particular, the invention relates inter alia to phagocytic cells comprising polyhedrin protein crystals, wherein the crystals themselves encapsulate therapeutic and/or diagnostic proteins. The invention also provides therapies using these cells.Type: ApplicationFiled: November 26, 2020Publication date: January 5, 2023Inventors: Michael Howard JONES, Christian PERNSTICH, Astrid WENDLER, Nicholas JAMES
-
Publication number: 20220348555Abstract: The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula (I) or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, R2 and R3 are as defined in the description. HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).Type: ApplicationFiled: April 12, 2021Publication date: November 3, 2022Applicant: Pfizer Inc.Inventors: Ariamala Gopalsamy, Shawn Cabral, Agustin Casimiro-Garcia, Ming Zhu Chen, Chulho Choi, Robert Lee Dow, Olugbeminiyi Omezia Fadeyi, David Hepworth, Jayasankar Jasti, Lyn Howard Jones, Arjun Venkat Narayanan, Mihir Dineshkumar Parikh, David Walter Piotrowski, Lee Richard Roberts, Ralph Pelton Robinson, Jr., Hatice Gizem Yayla
-
Publication number: 20220282017Abstract: The invention is directed to latent metathesis-active resin compositions and additive manufacturing approaches. The latent metathesis-active compositions comprise at least one latent metathesis catalyst, at least one curable metathesis-active monomer, and optional fillers, photosensitizers, and/or a secondary monomer resin system for dual-cure. A method comprises extruding a latent metathesis-active resin from a dispensing apparatus and spatially triggering a ring-opening metathesis polymerization by directed irradiation with light or directed application of a thermal stimuli for direct-ink write printing of objects. Another method uses a latent metathesis-active resin for vat photopolymerization and stereolithographic printing of objects.Type: ApplicationFiled: February 22, 2022Publication date: September 8, 2022Inventors: Leah Appelhans, Samuel Leguizamon, Brad Howard Jones, Adam Wade Cook
-
Publication number: 20210371575Abstract: Novel polymers are depolymerizable by metathesis of a cleavable unit. As an example, a series of linear and crosslinked polyurethanes were prepared that can be selectively depolymerized under mild conditions. Two unique polyols were synthesized bearing unsaturated units in a configuration designed to favor ring-closing metathesis to five- and six-membered cycloalkenes. These polyols were co-polymerized with toluene diisocyanate to generate linear polyurethanes and trifunctional hexamethylene- and diphenylmethane-based isocyanates to generate crosslinked polyurethanes. The polyol design is such that the ring-closing metathesis reaction cleaves the backbone of the polymer chain. Upon exposure to dilute solutions of Grubbs' catalyst under ambient conditions, the polyurethanes were rapidly depolymerized to low molecular weight, soluble products bearing vinyl and cycloalkene functionalities. These functionalities enabled further re-polymerization by traditional strategies for polymerization of double bonds.Type: ApplicationFiled: April 29, 2021Publication date: December 2, 2021Inventors: Brad Howard Jones, Chad Lynn Staiger
-
Patent number: 11014908Abstract: The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula (I) or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, R2 and R3 are as defined in the description. HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).Type: GrantFiled: November 26, 2019Date of Patent: May 25, 2021Assignee: Pfizer Inc.Inventors: Ariamala Gopalsamy, Arjun Venkat Narayanan, Agustin Casimiro-Garcia, Chulho Choi, David Hepworth, David Walter Piotrowski, Hatice Gizem Yayla, Jayasankar Jasti, Lee Richard Roberts, Lyn Howard Jones, Mihir Dineshkumar Parikh, Ming Zhu Chen, Olugbeminiyi Omezia Fadeyi, Ralph Pelton Robinson, Jr., Robert Lee Dow, Shawn Cabral
-
Publication number: 20200277570Abstract: A method of altering cells comprising culturing them in a growth factor gradient, wherein said gradient is provided by a polyhedra delivery system (PODS) that releases the growth factor to set up the gradient.Type: ApplicationFiled: April 11, 2018Publication date: September 3, 2020Inventors: Yuka Matsuzaki, Hajime Mori, Christian Pernstich, Michael Howard Jones
-
Publication number: 20200172512Abstract: The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula (I) or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, R2 and R3 are as defined in the description. HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).Type: ApplicationFiled: November 26, 2019Publication date: June 4, 2020Applicant: Pfizer Inc.Inventors: Ariamala Gopalsamy, Arjun Venkat Narayanan, Agustin Casimiro-Garcia, Chulho Choi, David Hepworth, David Walter Piotrowski, Hatice Gizem Yayla, Jayasankar Jasti, Lee Richard Roberts, Lyn Howard Jones, Mihir Dineshkumar Parikh, Ming Zhu Chen, Olugbeminiyi Omezia Fadeyi, Ralph Pelton Robinson, JR., Robert Lee Dow, Shawn Cabral
-
Patent number: 9920048Abstract: The present invention provides methods of inhibiting Raf kinase activity in a patient, the method comprising administering to the patient a compound having formula I: or a pharmaceutically acceptable salt thereof, wherein Rx, Ry, R1, L1, L2, Cy1, and Cy2 are as defined as set forth in the specification.Type: GrantFiled: December 15, 2016Date of Patent: March 20, 2018Assignees: Millennium Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc.Inventors: Weirong Chen, Jennifer Cossrow, Lloyd Franklin, Bing Guan, John Howard Jones, Gnanasambandam Kumaravel, Benjamin Lane, Adam Littke, Alexey Lugovskoy, Hairuo Peng, Noel Powell, Brian C. Raimundo, Hiroko Tanaka, Jeffrey Vessels, Thomas Wynn, Zhili Xin
-
Publication number: 20170275275Abstract: The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I), or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3a, R3b and R4 are as defined in the description. Nav1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.Type: ApplicationFiled: May 29, 2015Publication date: September 28, 2017Inventors: ALAN DANIEL BROWN, LYN HOWARD JONES, BRIAN EDWARD MARRON, DAVID JAMES RAWSON, THOMAS RYCKMANS, ROBERT IAN STORER, NIGEL ALAN SWAIN, CHRISTOPHER WILLIAM WEST